Achilles Therapeutics plc financial data

Location
London, United Kingdom
Fiscal year end
31 December
Latest financial report
6-K - Q2 2024 - 14 Aug 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.1M shares +0.37%
Common Stock, Shares, Outstanding 41.1M shares +0.35%
Common Stock, Value, Issued 54K USD 0%
Weighted Average Number of Shares Outstanding, Basic 40.4M shares +1.14%
Weighted Average Number of Shares Outstanding, Diluted 40.4M shares +1.14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.6M USD -1.01%
General and Administrative Expense 4.16M USD -3.57%
Operating Income (Loss) -17.8M USD +1.62%
Nonoperating Income (Expense) 1.43M USD +17.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.4M USD +3.01%
Income Tax Expense (Benefit) 8K USD
Net Income (Loss) Attributable to Parent -16.4M USD +2.77%
Earnings Per Share, Basic -0.41 USD/shares +2.38%
Earnings Per Share, Diluted -0.41 USD/shares +2.38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 95.1M USD -33.8%
Other Assets, Current 2.13M USD -39.7%
Assets, Current 118M USD -32.8%
Deferred Income Tax Assets, Net 41K USD -77.8%
Property, Plant and Equipment, Net 6.95M USD -36.5%
Operating Lease, Right-of-Use Asset 4.17M USD -50.3%
Other Assets, Noncurrent 2.16M USD -31.7%
Assets 131M USD -33.7%
Accounts Payable, Current 2.87M USD -58.4%
Employee-related Liabilities, Current 2.11M USD -12.2%
Accrued Liabilities, Current 7.23M USD -4.55%
Liabilities, Current 14.3M USD -25.2%
Operating Lease, Liability, Noncurrent 258K USD -93.5%
Other Liabilities, Noncurrent 1.16M USD +18.9%
Liabilities 15.7M USD -34.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -14M USD -0.82%
Retained Earnings (Accumulated Deficit) -289M USD -28.5%
Stockholders' Equity Attributable to Parent 115M USD -33.6%
Liabilities and Equity 131M USD -33.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 41.1M shares +0.35%
Common Stock, Shares, Issued 41.1M shares +0.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 95.2M USD -33.8%
Deferred Tax Assets, Valuation Allowance 37.6M USD +12.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.25 pure
Deferred Tax Assets, Gross 37.6M USD +11.6%
Operating Lease, Liability 4.46M USD -48.3%
Depreciation 1.2M USD -7.69%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.2M USD -24.2%
Lessee, Operating Lease, Liability, to be Paid 4.66M USD -49%
Property, Plant and Equipment, Gross 22.1M USD +2.47%
Operating Lease, Liability, Current 4.21M USD -9.69%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.1M USD -67%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.44M USD -48.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 197K USD -61.1%
Deferred Tax Assets, Operating Loss Carryforwards 30.4M USD -13.3%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 418M USD +1.39%
Deferred Tax Assets, Net of Valuation Allowance 41K USD -83.7%
Share-based Payment Arrangement, Expense 1.31M USD -22.9%